Revolution Medicines, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Revolution Medicines, Inc. | ||
| Date: February 25, 2026 | By: | /s/ Mark A. Goldsmith |
|---|---|---|
| Mark A. Goldsmith, M.D., Ph.D. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark A. Goldsmith, M.D., Ph.D., Jack Anders and Jeff Cislini and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this annual report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Mark A. Goldsmith | President, Chief Executive Officer and Director | February 25, 2026 |
| Mark A. Goldsmith, M.D., Ph.D. | (Principal Executive Officer) | |
| /s/ Jack Anders | Chief Financial Officer | February 25, 2026 |
| Jack Anders | (Principal Financial and Accounting Officer) | |
| /s/ Elizabeth McKee Anderson | Director | February 25, 2026 |
| Elizabeth McKee Anderson | ||
| /s/ Flavia Borellini | Director | February 25, 2026 |
| Flavia Borellini, Ph.D. | ||
| /s/ Alexis Borisy | Director | February 25, 2026 |
| Alexis Borisy | ||
| /s/ Frank Clyburn | Director | February 25, 2026 |
| Frank Clyburn | ||
| /s/ Sandra Horning | Director | February 25, 2026 |
| Sandra J. Horning, M.D. | ||
| /s/ Lorence Kim | Director | February 25, 2026 |
| Lorence Kim, M.D. | ||
| /s/ Sushil Patel | Director | February 25, 2026 |
| Sushil Patel, Ph.D. | ||
| /s/ Thilo Schroeder | Director | February 25, 2026 |
| Thilo Schroeder, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.